Mineralys posts pivotal wins, readies pre‑NDA with $325M but faces high cash burn, safety risks

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) - quick read

Snapshot - what's happening inside
* Company is a clinical‑stage biotech focused on lorundrostat (aldosterone synthase inhibitor) across uncontrolled/resistant hypertension, CKD and obstructive sleep apnea.
* Pivotal trials Launch‑HTN and Advance‑HTN met primary endpoints (statistically significant, clinically meaningful). Company plans a pre‑NDA meeting with FDA in Q4 2025.
* Phase 2 Explore‑CKD positive (systolic BP and UACR reductions). Explore‑OSA underway; topline expected H1 2026.
* Management is building commercial readiness while continuing clinical development and dosing in Transform‑HTN extension trial.

Key financials (as reported - amounts in thousands unless noted)
* Cash and cash equivalents: $101,788 (June 30, 2025).
* Investments: $223,128 (June 30, 2025).
* Cash, cash equivalents and investments (company stated): $324.9 million as of June 30, 2025.
* Total assets: $335,724; total current liabilities: $22,173; total stockholders' equity: $313,551 (June 30, 2025).
* Accumulated deficit: $(388,003).
* Shares outstanding: 65,725,409 (June 30, 2025); 66,295,184 shares outstanding as of Aug 7, 2025.
* Three months ended June 30, 2025 - Net loss: $(43,274). R&D: $38,278; G&A: $8,468.
* Six months ended June 30, 2025 - Net loss: $(85,485). R&D: $76,157; G&A: $15,036. Net loss per share (basic & diluted): $(1.44) for six months; Q2 net loss per share $(0.66).
* Weighted‑average shares used (Q2 2025): 65,451,297.
* Cash used in operating activities (six months): $(75,656). Cash used in investing activities: $(135,757). Cash provided by financing: $199,110. Net change in cash: $(12,303).

Income statement - positives
* Clinical milestone progress turned into tangible value: successful pivotal outcomes reduce development risk and support regulatory pathway (pre‑NDA planned).
* Q2 2025 R&D expense down slightly vs Q2 2024 ($38,278 vs $39,273), reflecting the conclusion of certain pivotal program costs. That can moderate near‑term cash burn from trial closeouts.
* Company raised significant new capital in 2025: gross proceeds from public offering (14,907,406 shares at $13.50) - net proceeds approx $188.7 million - plus ATM and prior private placement proceeds. That increased liquidity and extended runway (management: sufficient for at least 12 months).

Income statement - negatives / watchlist
* Operating losses remain large and growing year‑to‑date: six‑month net loss widened to $(85,485) (2025) from $(72,522) (2024).
* G&A increased materially (Q2 2025 G&A $8,468 vs Q2 2024 $5,895); six‑month G&A up $4.5M - higher overhead and commercialization build costs are accelerating burn.
* Cash used in operations increased to $75.7M for six months - meaningful ongoing cash burn despite recent financings.
* Accumulated deficit at $(388,003) and potential future cash needs remain (no product revenues). Company says additional funding may be required beyond current runway.
* Dilution: recent equity raises and outstanding options (~6,993,414 options) and pre‑funded warrants (549,755) increase potential share count and dilute existing holders.
* Clinical safety signals to monitor: hyperkalemia and SAEs varied across trials (Advance‑HTN had higher TE‑SAE rates vs placebo; Explore‑CKD showed confirmed hyperkalemia 5% on lorundrostat). These are manageable but will be scrutinized by regulators and payors.

Material commitments & financial obligations
* License obligations to Mitsubishi Tanabe include up to $155.0M in commercial milestone payments plus up to $10.0M for a second indication, and tiered royalties (mid‑single digits to 10% of net sales).
* No revenue history; all operations funded via equity/private financings. Since inception raised gross proceeds ≈ $717.4M (company disclosure).

Risks vs catalysts (near term)
* Catalysts: pre‑NDA meeting (Q4 2025), potential NDA submission, Explore‑OSA topline (H1 2026), continued Transform‑HTN extension data - all could re‑rate valuation if positive.
* Risks: need for additional capital after current runway; regulatory sensitivity to safety findings (potassium/eGFR effects); commercialization execution and pricing/reimbursement unknowns; dilution from future financings.

Bottom line - concise take
* Mineralys (NASDAQ: MLYS) has advanced from development risk reduction to regulatory preparation after strong pivotal and Phase 2 data. Financially it entered H2 2025 with substantial cash + investments (~$324.9M) thanks to a large public offering, but cash burn is high (operating cash use ~$75.7M in six months) and the company remains pre‑revenue. Investors should weigh the near‑term regulatory and commercial catalysts against ongoing losses, dilution risk and safety monitoring items (hyperkalemia/SAEs) when assessing upside vs downside.

Source: Mineralys Therapeutics, Inc. Form 10‑Q for quarter ended June 30, 2025 (figures presented as reported).